WallStreetZenWallStreetZen

NASDAQ: ARQT
Arcutis Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ARQT

Based on 6 analysts offering 12 month price targets for Arcutis Biotherapeutics Inc

Min Forecast
$34.00+29.62%
Avg Forecast
$36.67+39.79%
Max Forecast
$40.00+52.5%

Should I buy or sell ARQT stock?

Based on 6 analysts offering ratings for Arcutis Biotherapeutics Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ARQT stock forecasts and price targets.

ARQT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-06
lockedlocked$00.00+00.00%2026-08-06Find Out Why
lockedlocked$00.00+00.00%2026-08-06
lockedlocked$00.00+00.00%2026-03-02
lockedlocked$00.00+00.00%2026-02-26
HC Wainwright & Co.
Top 2%
99
BuyMaintains$34.00+29.62%2026-02-26

1 of 1

Forecast return on equity

Is ARQT forecast to generate an efficient return?

Company
162.86%
Industry
76.32%
Market
171.51%
ARQT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ARQT forecast to generate an efficient return on assets?

Company
73.53%
Industry
38.75%
ARQT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARQT earnings per share forecast

What is ARQT's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.16-23.38%
Avg 2 year Forecast
$1.06+405.1%
Avg 3 year Forecast
$1.89+799.86%
ARQT's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ARQT revenue forecast

What is ARQT's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$510.1M+9.94%
Avg 2 year Forecast
$660.2M+42.28%
Avg 3 year Forecast
$801.0M+72.64%
ARQT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARQT earnings growth forecast

How is ARQT forecast to perform vs Biotechnology companies and vs the US market?

Company
108%
Industry
11.99%
Market
30.88%
ARQT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ARQT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ARQT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ARQT revenue growth forecast

How is ARQT forecast to perform vs Biotechnology companies and vs the US market?

Company
19.96%
Industry
33.17%
Market
13.45%
ARQT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARQT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARQT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARQT$26.23$36.67+39.79%Strong Buy
NAMS$27.62$47.67+72.58%Strong Buy
ALMS$25.37$41.63+64.07%Strong Buy
MBX$66.01$83.75+26.87%Strong Buy
QURE$45.00$62.89+39.75%Strong Buy
View Top Biotech Stocks

Arcutis Biotherapeutics Stock Forecast FAQ

Is Arcutis Biotherapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ARQT) stock is to Strong Buy ARQT stock.

Out of 6 analysts, 3 (50%) are recommending ARQT as a Strong Buy, 3 (50%) are recommending ARQT as a Buy, 0 (0%) are recommending ARQT as a Hold, 0 (0%) are recommending ARQT as a Sell, and 0 (0%) are recommending ARQT as a Strong Sell.

If you're new to stock investing, here's how to buy Arcutis Biotherapeutics stock.

What is ARQT's earnings growth forecast for 2026-2028?

(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual earnings growth rate of 108% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and it is also forecast to beat the US market's average forecast earnings growth rate of 30.88%.

Arcutis Biotherapeutics's earnings in 2026 is $28,519,000.On average, 10 Wall Street analysts forecast ARQT's earnings for 2026 to be $20,223,837, with the lowest ARQT earnings forecast at -$6,158,906, and the highest ARQT earnings forecast at $44,080,171. On average, 10 Wall Street analysts forecast ARQT's earnings for 2027 to be $133,321,463, with the lowest ARQT earnings forecast at $59,125,498, and the highest ARQT earnings forecast at $212,482,260.

In 2028, ARQT is forecast to generate $237,520,099 in earnings, with the lowest earnings forecast at $140,423,059 and the highest earnings forecast at $358,976,241.

What is ARQT's revenue growth forecast for 2026-2028?

(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 19.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.45%.

Arcutis Biotherapeutics's revenue in 2026 is $463,981,000.On average, 10 Wall Street analysts forecast ARQT's revenue for 2026 to be $64,115,469,306, with the lowest ARQT revenue forecast at $60,431,437,929, and the highest ARQT revenue forecast at $67,492,812,298. On average, 10 Wall Street analysts forecast ARQT's revenue for 2027 to be $82,978,061,893, with the lowest ARQT revenue forecast at $76,088,885,511, and the highest ARQT revenue forecast at $92,661,370,569.

In 2028, ARQT is forecast to generate $100,679,260,761 in revenue, with the lowest revenue forecast at $88,728,469,109 and the highest revenue forecast at $114,147,154,382.

What is ARQT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ARQT) forecast ROA is 73.53%, which is higher than the forecast US Biotechnology industry average of 38.75%.

What is ARQT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ARQT price target, the average ARQT price target is $36.67, with the highest ARQT stock price forecast at $40.00 and the lowest ARQT stock price forecast at $34.00.

On average, Wall Street analysts predict that Arcutis Biotherapeutics's share price could reach $36.67 by Aug 6, 2027. The average Arcutis Biotherapeutics stock price prediction forecasts a potential upside of 39.79% from the current ARQT share price of $26.23.

What is ARQT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ARQT) Arcutis Biotherapeutics's current Earnings Per Share (EPS) is $0.21. On average, analysts forecast that ARQT's EPS will be $0.16 for 2026, with the lowest EPS forecast at -$0.05, and the highest EPS forecast at $0.35. On average, analysts forecast that ARQT's EPS will be $1.06 for 2027, with the lowest EPS forecast at $0.47, and the highest EPS forecast at $1.69. In 2028, ARQT's EPS is forecast to hit $1.89 (min: $1.12, max: $2.86).

What is ARQT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ARQT) forecast ROE is 162.86%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.